Compare KKR & Co Inc (KKR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Viatris Inc — how do they compare? KKR & Co Inc trades at $96.97 (market cap $87.07B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: KKR & Co Inc is far larger — about 4.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| KKR | VTRS | |
|---|---|---|
Market Cap | $87.07B | $19.79B |
Sector | Financials | Health |
52-Week High | $152.16 | $17.39 |
52-Week Low | $83.88 | $8.74 |
Enterprise Value | $12.59B | $32.00B |
Dividend Yield | 0.77% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $97.11, down 3.79% for the day, with a bullish technical signal and strong analyst backing. Recent earnings beat expectations in Q1 2026, and the firm is expanding through strategic ventures like a $1.3 billion renewable energy platform in South Korea and a $4.2 billion acquisition of EDF's North American operations. Financials show robust revenue of $19.21 billion in 2025 and a net income margin of 14.51%, though cash flow from operations has been volatile.
The outlook for KKR is positive, supported by a consensus price target of $120.75 and 89% buy ratings. Key opportunities include growth in renewable energy and private credit, while risks involve high leverage with long-term debt of $49.91 billion and dependence on capital market conditions. Investors should monitor the Q2 2026 earnings release on July 30, 2026, for further direction.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
